CareDx reports preliminary Q4 revenue up 30% YoY to ~$85.5M; guides 2025 revenue $370M

CareDx, Inc.

2024-FY EPS reported $0.93 revenue$333,785,000

Q4 revenue expected $85M-$86M, up ~30% YoY; testing services revenue $62.5M-$63.5M, up 35%.
Full year 2024 revenue $332M-$333M; GAAP loss $58M-$60M; adjusted EBITDA gain $25M-$26M.
Testing services volume ~45,500 in Q4, up 14% YoY; sixth consecutive quarter of volume growth.
Cash, equivalents, and marketable securities ~$261M as of Dec 31, 2024, up $26M YoY.
2025 revenue guidance of $370M; targeting $500M revenue and 20% adjusted EBITDA by 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.